Skip to main content
OpenTrials
Completed

NCT Number: NCT03793400

Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Choroidal Neovascularization Choroid Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Panuveitis Pathologic Processes Pathological Conditions, Signs and Symptoms Punctate Inner Choroidopathy Uveal Diseases Uveitis Uveitis, Posterior White Dot Syndromes

Sex eligibility

All sexes

Study type

Observational

Primary location

Changhua Christian Hospital

Changhua, Taiwan

About this study

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

The age, sex, best corrected visual acuity (BCVA) in Snellen chart, and refractive status for each patient were recorded. All patients had thorough clinical examinations, including slit lamp biomicroscopy, indirect ophthalmoloscopy, and spectral domain optical coherence tomography during each visit. Fundus photography, fluorescein angiography, and indocyanine angiography were performed on all patients. OCT angiography was performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization.
  • Follow up over 4 years.

Exclusion criteria

  • Patients were not punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization
  • Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization but loss follow over 1 year.

Treatment and study plan

Bevacizumab Injection

Drug

Anti-vascular endothelial growth factor (VEGF)

Primary outcomes

  1. Wilcoxon Signed-Rank test

    Time frame: Baseline,48 month.

    A statistical comparison of average of two dependent samples

Secondary outcomes

  1. visual acuity

    Time frame: Baseline,48 month.

    visual acuity in logMAR

Sponsors and collaborators

Lead sponsor

Changhua Christian Hospital

Other

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 4, 2019
Registry last updated
Jan 8, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.